Loading ...Eli Lilly Romania pharmaceutical company plans to launch a product for cardiovascular diseases, which could lead to a 37% rise in turnover. According to Radu Rasinar, general manager of Eli Lilly Romania, the new product could generate some 6.4 – 12.8 million euro in sales.
The company will launch at least six products in the coming 2-3 years. Eli Lilly expects a turnover of 38 million euro this year, 10% higher than in 2007. The Romanian market accounts for 3 – 4% of total European sales. The company claims some 20% of the local diabetes drug market, which yields 25% of Eli Lilly’s turnover.
Loading ...
Comentează acest articol